The shares of global leader in allogeneic cellular medicines for inflammatory diseases, Mesoblast Limited (NASDAQ: MESO) are rising on the charts today, up 10.80% to $8.00 at last check-in premarket trades. Mesoblast stock closed Thursday session at $7.22, falling -1.37%. The volume for MESO stock was 0.48 million, compared to 281.32K daily average. For positive results of its lead candidate for COVID-19, MESO stock has been rising.
The study found what?
Mesoblast has been designing allogeneic (off-the-shelf) cellular medicines for almost a decade to treat severe and life-threatening inflammatory conditions. Using the MESO proprietary mesenchymal lineage cell therapy platform, the company created a pipeline of late-stage product candidates that deliver significant reduction in the damaging inflammatory process by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system.
Read More
Yesterday, Mesoblast announced that the 60-day results from a randomized controlled trial that included 222 ventilator-dependent COVID-19 patients with moderate to severe ARDS had been published. This trial was halted at the third interim analysis, as previously reported.
- In the pre-specified age group below 65, MESO’s Remestemcel-L reduced mortality by 46% through day 60, but not in those 65 or older.
- In patients under the age of 65, Remestemcel-L has been shown to reduce mortality by 75% and increase days alive when combined with dexamethasone, in comparison with patients on the same dose of dexamethasone.
- A total of 222 patients mechanically ventilated with severe or moderate ARDS across the US participated in the MESO trial.
- Of that group, 217 people were randomized 1:1 to either standard medical care alone or standard medical care plus two intravenous infusions of remestemcel-L at a dose 2 million cells/kg, administered within three days of each other.
Comparison:
During the earlier compassionate use program by Mesoblast (MESO), the same remestemcel-L dosing regimen was used on 11 of 12 patients, all younger than 65 and MESO found 75% of them achieved successful ventilation relief.
